TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.
Jiangsu Hengrui Pharmaceuticals has entered into a significant collaboration agreement with GlaxoSmithKline (GSK) to grant GSK exclusive worldwide rights, excluding certain regions, for HRS-9821, a PDE3/4 inhibitor in development for chronic obstructive pulmonary disease (COPD). This agreement also includes options for GSK to obtain licenses for up to 11 additional programs, potentially enhancing Hengrui’s global presence and impact in the pharmaceutical industry.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$134.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of innovative drugs. The company is involved in the pharmaceutical industry, primarily offering products and services related to drug development and manufacturing, with a market focus on both domestic and international markets.
Average Trading Volume: 5,720,546
Current Market Cap: HK$409.1B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.